Volume overload: Difference between revisions

(Created page with "''Volume overload is a clinical syndrome of extracellular fluid (ECF) expansion due to excess total body sodium. It is a common ED presentation that requires identification of the underlying cause and targeted decongestion.'' ==Background== *Definition: expansion of extracellular fluid volume due to increased total body sodium content, leading to edema, pulmonary congestion, and/or third-space fluid accumulation **An increase in total body sodium raises plasma osmolalit...")
 
(Formatting: moved intro to Background bullets, removed excessive bold)
Line 1: Line 1:
''Volume overload is a clinical syndrome of extracellular fluid (ECF) expansion due to excess total body sodium. It is a common ED presentation that requires identification of the underlying cause and targeted decongestion.''
==Background==
*''Volume overload is a clinical syndrome of extracellular fluid (ECF) expansion due to excess total body sodium.
*It is a common ED presentation that requires identification of the underlying cause and targeted decongestion.''
 


==Background==
*Definition: expansion of extracellular fluid volume due to increased total body sodium content, leading to edema, pulmonary congestion, and/or third-space fluid accumulation
*Definition: expansion of extracellular fluid volume due to increased total body sodium content, leading to edema, pulmonary congestion, and/or third-space fluid accumulation
**An increase in total body sodium raises plasma osmolality, triggering compensatory water retention
**An increase in total body sodium raises plasma osmolality, triggering compensatory water retention
**Clinically apparent edema typically requires >2.5 L of excess ECF<ref name="Merck">Volume Overload. Merck Manual Professional Edition. Revised May 2024. https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/fluid-metabolism/volume-overload</ref>
**Clinically apparent edema typically requires >2.5 L of excess ECF<ref name="Merck">Volume Overload. Merck Manual Professional Edition. Revised May 2024. https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/fluid-metabolism/volume-overload</ref>
**Serum sodium concentration can be high, low, or normal in volume-overloaded patients (despite increased total body sodium)
**Serum sodium concentration can be high, low, or normal in volume-overloaded patients (despite increased total body sodium)
*'''Key distinction''': Volume overload ≠ dehydration. Patients can be total-body volume overloaded but intravascularly depleted (e.g., cirrhosis, nephrotic syndrome)
*Key distinction: Volume overload ≠ dehydration. Patients can be total-body volume overloaded but intravascularly depleted (e.g., cirrhosis, nephrotic syndrome)


===Pathophysiology===
===Pathophysiology===
Line 14: Line 16:
**ADH release → free water retention
**ADH release → free water retention
**Suppression of natriuretic peptides (ANP, BNP) → reduced sodium excretion
**Suppression of natriuretic peptides (ANP, BNP) → reduced sodium excretion
*'''Heart failure''': reduced cardiac output → decreased effective circulating volume → neurohormonal activation → sodium/water retention
*Heart failure: reduced cardiac output → decreased effective circulating volume → neurohormonal activation → sodium/water retention
*'''Cirrhosis''': splanchnic vasodilation → arterial underfilling → neurohormoral activation → sodium/water retention with third-spacing into peritoneum
*Cirrhosis: splanchnic vasodilation → arterial underfilling → neurohormoral activation → sodium/water retention with third-spacing into peritoneum
*'''Nephrotic syndrome''': hypoalbuminemia → decreased oncotic pressure → edema; also primary renal sodium retention via ENaC activation in collecting duct
*Nephrotic syndrome: hypoalbuminemia → decreased oncotic pressure → edema; also primary renal sodium retention via ENaC activation in collecting duct
*'''Renal failure''': impaired GFR and tubular sodium excretion → direct sodium/water retention
*Renal failure: impaired GFR and tubular sodium excretion → direct sodium/water retention


===Epidemiology===
===Epidemiology===
Line 27: Line 29:
==Clinical Features==
==Clinical Features==
===Symptoms===
===Symptoms===
*'''Cardiac'''
*Cardiac
**Dyspnea (exertional → orthopnea → PND → dyspnea at rest)
**Dyspnea (exertional → orthopnea → PND → dyspnea at rest)
**Bendopnea (dyspnea within 30 seconds of bending forward)
**Bendopnea (dyspnea within 30 seconds of bending forward)
**Exercise intolerance, fatigue
**Exercise intolerance, fatigue
**Chest tightness
**Chest tightness
*'''Systemic'''
*Systemic
**Weight gain (often 2-10 kg over days to weeks)
**Weight gain (often 2-10 kg over days to weeks)
**Abdominal distension, early satiety, nausea (hepatic/splanchnic congestion)
**Abdominal distension, early satiety, nausea (hepatic/splanchnic congestion)
Line 38: Line 40:


===Signs===
===Signs===
*'''Pulmonary congestion'''
*Pulmonary congestion
**Crackles/rales (may be absent in chronic HF due to lymphatic compensation)
**Crackles/rales (may be absent in chronic HF due to lymphatic compensation)
**Wheezing ("cardiac asthma")
**Wheezing ("cardiac asthma")
**Hypoxia, tachypnea
**Hypoxia, tachypnea
**Pleural effusions (often right-sided or bilateral; isolated left-sided effusion should raise suspicion for non-cardiac cause)
**Pleural effusions (often right-sided or bilateral; isolated left-sided effusion should raise suspicion for non-cardiac cause)
*'''Systemic venous congestion'''
*Systemic venous congestion
**Elevated JVP (>8 cm H2O)
**Elevated JVP (>8 cm H2O)
**Hepatojugular reflux
**Hepatojugular reflux
Line 49: Line 51:
**Ascites
**Ascites
**Hepatomegaly, RUQ tenderness (hepatic congestion)
**Hepatomegaly, RUQ tenderness (hepatic congestion)
*'''Cardiovascular'''
*Cardiovascular
**S3 gallop (volume overload, systolic dysfunction)
**S3 gallop (volume overload, systolic dysfunction)
**S4 gallop (diastolic dysfunction)
**S4 gallop (diastolic dysfunction)
Line 55: Line 57:
**Tachycardia (compensatory)
**Tachycardia (compensatory)
**Hypertension (common; SBP >160 in ~50% of ADHF presentations) or hypotension (low-output HF, cardiogenic shock)
**Hypertension (common; SBP >160 in ~50% of ADHF presentations) or hypotension (low-output HF, cardiogenic shock)
*'''Other'''
*Other
**Cool extremities, delayed capillary refill (if low cardiac output)
**Cool extremities, delayed capillary refill (if low cardiac output)
**Jaundice (congestive hepatopathy)
**Jaundice (congestive hepatopathy)
Line 93: Line 95:


====All patients====
====All patients====
*'''BNP or NT-proBNP'''
*BNP or NT-proBNP
**BNP >400 pg/mL or NT-proBNP >900 pg/mL (age-adjusted) strongly suggests HF as cause<ref>Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167.</ref>
**BNP >400 pg/mL or NT-proBNP >900 pg/mL (age-adjusted) strongly suggests HF as cause<ref>Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167.</ref>
**BNP <100 pg/mL or NT-proBNP <300 pg/mL makes HF unlikely
**BNP <100 pg/mL or NT-proBNP <300 pg/mL makes HF unlikely
**''Falsely low in obesity; falsely elevated in renal failure, AF, PE, sepsis''
**''Falsely low in obesity; falsely elevated in renal failure, AF, PE, sepsis''
*'''BMP/CMP''' — electrolytes, BUN, creatinine, glucose, calcium
*BMP/CMP — electrolytes, BUN, creatinine, glucose, calcium
*'''CBC''' — anemia (high-output HF), infection
*CBC — anemia (high-output HF), infection
*'''Urinalysis''' — proteinuria (nephrotic syndrome), casts (GN)
*Urinalysis — proteinuria (nephrotic syndrome), casts (GN)
*'''ECG''' — ischemia, arrhythmia, LVH, low voltage (tamponade/effusion)
*ECG — ischemia, arrhythmia, LVH, low voltage (tamponade/effusion)
*'''CXR''' — cardiomegaly, cephalization, Kerley B lines, pleural effusions, pulmonary edema
*CXR — cardiomegaly, cephalization, Kerley B lines, pleural effusions, pulmonary edema
*'''Pulse oximetry / ABG''' if respiratory distress
*Pulse oximetry / ABG if respiratory distress


====Cardiac suspected====
====Cardiac suspected====
*'''Point-of-care ultrasound (POCUS)''' — ''high yield in the ED''
*Point-of-care ultrasound (POCUS) — ''high yield in the ED''
**B-lines (≥3 per zone in ≥2 bilateral zones = pulmonary edema; LR+ ~7.4 for ADHF)<ref>Pivetta E, Goffi A, Lupia E, et al. Lung Ultrasound-Implemented Diagnosis of Acute Decompensated Heart Failure in the ED: A SIMEU Multicenter Study. Chest. 2015;148(1):202-210.</ref>
**B-lines (≥3 per zone in ≥2 bilateral zones = pulmonary edema; LR+ ~7.4 for ADHF)<ref>Pivetta E, Goffi A, Lupia E, et al. Lung Ultrasound-Implemented Diagnosis of Acute Decompensated Heart Failure in the ED: A SIMEU Multicenter Study. Chest. 2015;148(1):202-210.</ref>
**IVC assessment (dilated >2.1 cm with <50% collapsibility suggests elevated RA pressure)
**IVC assessment (dilated >2.1 cm with <50% collapsibility suggests elevated RA pressure)
Line 112: Line 114:
**Pleural effusions
**Pleural effusions
*[[Troponin]] — rule out ACS as precipitant
*[[Troponin]] — rule out ACS as precipitant
*'''Hepatic function panel''' — congestive hepatopathy
*Hepatic function panel — congestive hepatopathy
*'''Lactate''' — if concern for cardiogenic shock or hypoperfusion
*Lactate — if concern for cardiogenic shock or hypoperfusion
*'''TSH''' — if new HF or tachycardia-mediated
*TSH — if new HF or tachycardia-mediated


====Hepatic suspected====
====Hepatic suspected====
Line 131: Line 133:
===Diagnosis===
===Diagnosis===
*Volume overload is a '''clinical diagnosis''' supported by history, exam, and ancillary testing
*Volume overload is a '''clinical diagnosis''' supported by history, exam, and ancillary testing
*'''Identify the underlying cause''' — this drives specific management
*Identify the underlying cause — this drives specific management
*'''Assess hemodynamic profile''' using the Stevenson/Nohria classification for HF patients:
*Assess hemodynamic profile using the Stevenson/Nohria classification for HF patients:
**'''Warm and wet''' (adequate perfusion + congestion) — most common ADHF presentation (~70%)
**Warm and wet (adequate perfusion + congestion) — most common ADHF presentation (~70%)
**'''Cold and wet''' (poor perfusion + congestion) — cardiogenic shock spectrum
**Cold and wet (poor perfusion + congestion) — cardiogenic shock spectrum
**'''Warm and dry''' (adequate perfusion + euvolemic) — compensated HF
**Warm and dry (adequate perfusion + euvolemic) — compensated HF
**'''Cold and dry''' (poor perfusion + euvolemic) — low-output state without congestion
**Cold and dry (poor perfusion + euvolemic) — low-output state without congestion


==Management==
==Management==
===General Principles===
===General Principles===
*'''Identify and treat the precipitant''' — ACS, arrhythmia, medication nonadherence, dietary indiscretion, infection, PE, renal failure, uncontrolled HTN
*Identify and treat the precipitant — ACS, arrhythmia, medication nonadherence, dietary indiscretion, infection, PE, renal failure, uncontrolled HTN
*'''Treat respiratory distress first''' (airway management before diuresis)
*Treat respiratory distress first (airway management before diuresis)
*Obtain '''daily weights''' — best metric to follow decongestion progress
*Obtain '''daily weights''' — best metric to follow decongestion progress
*Goal: net negative fluid balance of 1-2 L/day (weight loss 0.5-1 kg/day); may be more aggressive in acute pulmonary edema<ref name="Merck"/>
*Goal: net negative fluid balance of 1-2 L/day (weight loss 0.5-1 kg/day); may be more aggressive in acute pulmonary edema<ref name="Merck"/>
Line 147: Line 149:


===Respiratory Support===
===Respiratory Support===
*'''Supplemental O2''' — titrate to SpO2 ≥90%
*Supplemental O2 — titrate to SpO2 ≥90%
*'''Non-invasive positive pressure ventilation (NIPPV)''' — ''first-line for acute cardiogenic pulmonary edema''
*Non-invasive positive pressure ventilation (NIPPV) — ''first-line for acute cardiogenic pulmonary edema''
**Reduces work of breathing, decreases preload and afterload, improves oxygenation
**Reduces work of breathing, decreases preload and afterload, improves oxygenation
**CPAP 5-10 cmH2O or BiPAP 10/5 cmH2O, titrate to effect
**CPAP 5-10 cmH2O or BiPAP 10/5 cmH2O, titrate to effect
**3CPAP RCT demonstrated reduced mortality and intubation rates vs standard O2<ref>Gray A, Goodacre S, Newby DE, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008;359(2):142-151.</ref>
**3CPAP RCT demonstrated reduced mortality and intubation rates vs standard O2<ref>Gray A, Goodacre S, Newby DE, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008;359(2):142-151.</ref>
*'''Intubation''' — if NIPPV fails, altered mental status, or inability to protect airway
*Intubation — if NIPPV fails, altered mental status, or inability to protect airway
**Beware hemodynamic compromise with induction agents and positive pressure ventilation in patients with poor cardiac reserve
**Beware hemodynamic compromise with induction agents and positive pressure ventilation in patients with poor cardiac reserve


===Vasodilators===
===Vasodilators===
''For hypertensive volume-overloaded patients (SBP >110-120 mmHg), especially with acute pulmonary edema''
''For hypertensive volume-overloaded patients (SBP >110-120 mmHg), especially with acute pulmonary edema''
*'''IV Nitroglycerin''' — ''drug of choice in acute cardiogenic pulmonary edema with adequate BP''
*IV Nitroglycerin — ''drug of choice in acute cardiogenic pulmonary edema with adequate BP''
**Start 5-20 mcg/min, titrate q3-5 min up to 200 mcg/min
**Start 5-20 mcg/min, titrate q3-5 min up to 200 mcg/min
**Reduces preload > afterload; improves coronary blood flow
**Reduces preload > afterload; improves coronary blood flow
**High-dose NTG (bolus 200-400 mcg then infusion) can rapidly reduce pulmonary edema symptoms
**High-dose NTG (bolus 200-400 mcg then infusion) can rapidly reduce pulmonary edema symptoms
**Avoid if SBP <90, severe aortic stenosis, recent PDE5 inhibitor use
**Avoid if SBP <90, severe aortic stenosis, recent PDE5 inhibitor use
*'''IV Nitroprusside''' — arteriolar and venous dilation; useful if severe afterload excess
*IV Nitroprusside — arteriolar and venous dilation; useful if severe afterload excess
**0.3-0.5 mcg/kg/min; max 2-3 mcg/kg/min
**0.3-0.5 mcg/kg/min; max 2-3 mcg/kg/min
**Risk of cyanide toxicity, coronary steal; generally second-line
**Risk of cyanide toxicity, coronary steal; generally second-line
*'''Consider nicardipine or clevidipine''' if concomitant [[hypertensive emergency]]
*Consider nicardipine or clevidipine if concomitant [[hypertensive emergency]]


===Diuretics===
===Diuretics===
Line 171: Line 173:


====Loop Diuretics (First-Line)====
====Loop Diuretics (First-Line)====
*'''IV furosemide''' is the most commonly used agent
*IV furosemide is the most commonly used agent
**'''Diuretic-naive patients''': Start 20-40 mg IV bolus
**Diuretic-naive patients: Start 20-40 mg IV bolus
**'''Chronic loop diuretic users''': Give IV dose ≥ home oral daily dose (high-dose strategy preferred)
**Chronic loop diuretic users: Give IV dose ≥ home oral daily dose (high-dose strategy preferred)
***The '''DOSE trial''' showed high-dose IV furosemide (2.5× oral dose) provided greater symptom relief, diuresis, and weight loss vs. low-dose (1× oral dose), with only transient increases in creatinine<ref name="DOSE">Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. doi:10.1056/NEJMoa1005419</ref>
***The '''DOSE trial''' showed high-dose IV furosemide (2.5× oral dose) provided greater symptom relief, diuresis, and weight loss vs. low-dose (1× oral dose), with only transient increases in creatinine<ref name="DOSE">Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. doi:10.1056/NEJMoa1005419</ref>
***No significant difference between bolus q12h vs. continuous infusion on primary outcomes<ref name="DOSE"/>
***No significant difference between bolus q12h vs. continuous infusion on primary outcomes<ref name="DOSE"/>
**Reassess urine output at 2 hours; if <100-150 mL/hr, double the dose<ref name="HF2022">Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063</ref>
**Reassess urine output at 2 hours; if <100-150 mL/hr, double the dose<ref name="HF2022">Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063</ref>
*'''Equivalent doses''': furosemide 40 mg IV = bumetanide 1 mg IV = torsemide 20 mg IV
*Equivalent doses: furosemide 40 mg IV = bumetanide 1 mg IV = torsemide 20 mg IV
*'''Bioavailability''': IV furosemide 100%, oral furosemide ~50% (variable; bumetanide and torsemide have more reliable oral absorption)
*Bioavailability: IV furosemide 100%, oral furosemide ~50% (variable; bumetanide and torsemide have more reliable oral absorption)


====Diuretic Resistance (Sequential Nephron Blockade)====
====Diuretic Resistance (Sequential Nephron Blockade)====
''If inadequate urine output despite escalating loop diuretic dose''
''If inadequate urine output despite escalating loop diuretic dose''
*'''Add thiazide-type diuretic''' for synergistic blockade at distal convoluted tubule
*Add thiazide-type diuretic for synergistic blockade at distal convoluted tubule
**Metolazone 2.5-5 mg PO (give 30 min before loop diuretic) '''OR'''
**Metolazone 2.5-5 mg PO (give 30 min before loop diuretic) '''OR'''
**Chlorothiazide 250-500 mg IV (if unable to take PO)
**Chlorothiazide 250-500 mg IV (if unable to take PO)
**Monitor closely for hypokalemia, hyponatremia, hypomagnesemia
**Monitor closely for hypokalemia, hyponatremia, hypomagnesemia
*'''Add acetazolamide''' — carbonic anhydrase inhibitor; blocks proximal tubular sodium reabsorption
*Add acetazolamide — carbonic anhydrase inhibitor; blocks proximal tubular sodium reabsorption
**The '''ADVOR trial''' (n=519) showed IV acetazolamide 500 mg daily added to loop diuretics significantly increased successful decongestion at 3 days (42.2% vs. 30.5%; RR 1.46, 95% CI 1.17-1.82; p<0.001), with shorter hospital stay and no difference in adverse events<ref name="ADVOR">Mullens W, Dauw J, Martens P, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. 2022;387(13):1185-1195. doi:10.1056/NEJMoa2203094</ref>
**The '''ADVOR trial''' (n=519) showed IV acetazolamide 500 mg daily added to loop diuretics significantly increased successful decongestion at 3 days (42.2% vs. 30.5%; RR 1.46, 95% CI 1.17-1.82; p<0.001), with shorter hospital stay and no difference in adverse events<ref name="ADVOR">Mullens W, Dauw J, Martens P, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. 2022;387(13):1185-1195. doi:10.1056/NEJMoa2203094</ref>
**Most effective in patients with elevated serum bicarbonate (metabolic alkalosis from chronic diuretic use)
**Most effective in patients with elevated serum bicarbonate (metabolic alkalosis from chronic diuretic use)
**''Note: ADVOR excluded patients on SGLT2 inhibitors; interaction unknown''
**''Note: ADVOR excluded patients on SGLT2 inhibitors; interaction unknown''
*'''Consider SGLT2 inhibitor''' (empagliflozin, dapagliflozin) — osmotic diuresis via glucosuria and natriuresis at proximal tubule; EMPULSE trial supports in-hospital initiation<ref>Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574.</ref>
*Consider SGLT2 inhibitor (empagliflozin, dapagliflozin) — osmotic diuresis via glucosuria and natriuresis at proximal tubule; EMPULSE trial supports in-hospital initiation<ref>Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574.</ref>


====Monitoring During Diuresis====
====Monitoring During Diuresis====
Line 202: Line 204:
===Inotropes===
===Inotropes===
''Reserved for "cold and wet" profile (low cardiac output + congestion) — cardiogenic shock spectrum''
''Reserved for "cold and wet" profile (low cardiac output + congestion) — cardiogenic shock spectrum''
*'''Dobutamine''' — beta-1 agonist; increases contractility and cardiac output
*Dobutamine — beta-1 agonist; increases contractility and cardiac output
**Start 2.5-5 mcg/kg/min, titrate to effect
**Start 2.5-5 mcg/kg/min, titrate to effect
**Shorter half-life, more easily titratable than milrinone
**Shorter half-life, more easily titratable than milrinone
*'''Milrinone''' — PDE-3 inhibitor; inotrope + vasodilator ("inodilator")
*Milrinone — PDE-3 inhibitor; inotrope + vasodilator ("inodilator")
**Load 50 mcg/kg over 10 min (often omitted), then 0.375-0.75 mcg/kg/min
**Load 50 mcg/kg over 10 min (often omitted), then 0.375-0.75 mcg/kg/min
**Renally cleared; accumulates in renal failure
**Renally cleared; accumulates in renal failure
Line 218: Line 220:


====Cirrhosis with Ascites====
====Cirrhosis with Ascites====
*'''Spironolactone''' is first-line (100 mg/day, max 400 mg/day) ± furosemide in 100:40 ratio
*Spironolactone is first-line (100 mg/day, max 400 mg/day) ± furosemide in 100:40 ratio
*Sodium restriction (<2 g/day)
*Sodium restriction (<2 g/day)
*'''Large-volume paracentesis''' for tense ascites or respiratory compromise
*Large-volume paracentesis for tense ascites or respiratory compromise
**Give albumin 6-8 g per liter removed if >5 L removed
**Give albumin 6-8 g per liter removed if >5 L removed
*Avoid NSAIDs (worsen renal sodium retention)
*Avoid NSAIDs (worsen renal sodium retention)
Line 252: Line 254:
*Maximize sequential nephron blockade (loop + thiazide + acetazolamide)
*Maximize sequential nephron blockade (loop + thiazide + acetazolamide)
*Consider hypertonic saline with furosemide (emerging evidence, not yet standard)
*Consider hypertonic saline with furosemide (emerging evidence, not yet standard)
*'''Ultrafiltration''' — mechanical fluid removal via venovenous access
*Ultrafiltration — mechanical fluid removal via venovenous access
**UNLOAD trial showed benefit in fluid removal; CARRESS-HF showed no benefit over stepped pharmacological therapy and more adverse events<ref>Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296-2304.</ref>
**UNLOAD trial showed benefit in fluid removal; CARRESS-HF showed no benefit over stepped pharmacological therapy and more adverse events<ref>Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296-2304.</ref>
**Reserve for truly refractory cases
**Reserve for truly refractory cases

Revision as of 16:07, 19 March 2026

Background

  • Volume overload is a clinical syndrome of extracellular fluid (ECF) expansion due to excess total body sodium.
  • It is a common ED presentation that requires identification of the underlying cause and targeted decongestion.


  • Definition: expansion of extracellular fluid volume due to increased total body sodium content, leading to edema, pulmonary congestion, and/or third-space fluid accumulation
    • An increase in total body sodium raises plasma osmolality, triggering compensatory water retention
    • Clinically apparent edema typically requires >2.5 L of excess ECF[1]
    • Serum sodium concentration can be high, low, or normal in volume-overloaded patients (despite increased total body sodium)
  • Key distinction: Volume overload ≠ dehydration. Patients can be total-body volume overloaded but intravascularly depleted (e.g., cirrhosis, nephrotic syndrome)

Pathophysiology

  • Reduced effective circulating volume (ECF within the arterial system effectively perfusing tissues) triggers neurohormonal activation[2]
    • Activation of RAAS → renal sodium and water retention
    • Sympathetic nervous system activation → systemic vasoconstriction
    • ADH release → free water retention
    • Suppression of natriuretic peptides (ANP, BNP) → reduced sodium excretion
  • Heart failure: reduced cardiac output → decreased effective circulating volume → neurohormonal activation → sodium/water retention
  • Cirrhosis: splanchnic vasodilation → arterial underfilling → neurohormoral activation → sodium/water retention with third-spacing into peritoneum
  • Nephrotic syndrome: hypoalbuminemia → decreased oncotic pressure → edema; also primary renal sodium retention via ENaC activation in collecting duct
  • Renal failure: impaired GFR and tubular sodium excretion → direct sodium/water retention

Epidemiology

  • Heart failure is the most common cause of volume overload presenting to the ED
    • >1 million HF hospitalizations annually in the US[3]
    • In-hospital mortality 4-14%; 1-year post-discharge mortality up to 30%[4]
  • Cirrhosis with ascites, nephrotic syndrome, and ESRD are other major causes

Clinical Features

Symptoms

  • Cardiac
    • Dyspnea (exertional → orthopnea → PND → dyspnea at rest)
    • Bendopnea (dyspnea within 30 seconds of bending forward)
    • Exercise intolerance, fatigue
    • Chest tightness
  • Systemic
    • Weight gain (often 2-10 kg over days to weeks)
    • Abdominal distension, early satiety, nausea (hepatic/splanchnic congestion)
    • Extremity swelling

Signs

  • Pulmonary congestion
    • Crackles/rales (may be absent in chronic HF due to lymphatic compensation)
    • Wheezing ("cardiac asthma")
    • Hypoxia, tachypnea
    • Pleural effusions (often right-sided or bilateral; isolated left-sided effusion should raise suspicion for non-cardiac cause)
  • Systemic venous congestion
    • Elevated JVP (>8 cm H2O)
    • Hepatojugular reflux
    • Peripheral pitting edema (lower extremities, sacral in bedridden patients)
    • Ascites
    • Hepatomegaly, RUQ tenderness (hepatic congestion)
  • Cardiovascular
    • S3 gallop (volume overload, systolic dysfunction)
    • S4 gallop (diastolic dysfunction)
    • Displaced PMI
    • Tachycardia (compensatory)
    • Hypertension (common; SBP >160 in ~50% of ADHF presentations) or hypotension (low-output HF, cardiogenic shock)
  • Other
    • Cool extremities, delayed capillary refill (if low cardiac output)
    • Jaundice (congestive hepatopathy)

Differential Diagnosis

Cardiac

Hepatic

Renal

Other

  • Iatrogenic (IV fluid overload, blood transfusion)
  • Pregnancy / preeclampsia
  • Severe hypoalbuminemia (malnutrition, protein-losing enteropathy)
  • Medication-related (NSAIDs, CCBs, thiazolidinediones, corticosteroids)
  • DVT / venous insufficiency (unilateral edema — not true volume overload)
  • Lymphedema (non-pitting — not true volume overload)
  • Myxedema (hypothyroidism)

Evaluation

Workup

Tailor workup to suspected underlying cause

All patients

  • BNP or NT-proBNP
    • BNP >400 pg/mL or NT-proBNP >900 pg/mL (age-adjusted) strongly suggests HF as cause[5]
    • BNP <100 pg/mL or NT-proBNP <300 pg/mL makes HF unlikely
    • Falsely low in obesity; falsely elevated in renal failure, AF, PE, sepsis
  • BMP/CMP — electrolytes, BUN, creatinine, glucose, calcium
  • CBC — anemia (high-output HF), infection
  • Urinalysis — proteinuria (nephrotic syndrome), casts (GN)
  • ECG — ischemia, arrhythmia, LVH, low voltage (tamponade/effusion)
  • CXR — cardiomegaly, cephalization, Kerley B lines, pleural effusions, pulmonary edema
  • Pulse oximetry / ABG if respiratory distress

Cardiac suspected

  • Point-of-care ultrasound (POCUS) — high yield in the ED
    • B-lines (≥3 per zone in ≥2 bilateral zones = pulmonary edema; LR+ ~7.4 for ADHF)[6]
    • IVC assessment (dilated >2.1 cm with <50% collapsibility suggests elevated RA pressure)
    • LV function (gross EF estimation)
    • Pericardial effusion
    • Pleural effusions
  • Troponin — rule out ACS as precipitant
  • Hepatic function panel — congestive hepatopathy
  • Lactate — if concern for cardiogenic shock or hypoperfusion
  • TSH — if new HF or tachycardia-mediated

Hepatic suspected

  • LFTs, albumin, INR
  • Abdominal ultrasound with Doppler (portal hypertension, ascites)
  • Paracentesis (if new ascites or concern for SBP) — cell count, albumin, culture, total protein, SAAG

Renal suspected

  • Urine sodium
    • <10 mEq/L in HF, cirrhosis, nephrotic syndrome (avid renal sodium retention)
    • >20 mEq/L in renal failure (impaired tubular reabsorption)[1]
  • Urine protein/creatinine ratio or 24-hour urine protein
  • Renal ultrasound
  • Consider complement levels, ANA, ANCA if GN suspected

Diagnosis

  • Volume overload is a clinical diagnosis supported by history, exam, and ancillary testing
  • Identify the underlying cause — this drives specific management
  • Assess hemodynamic profile using the Stevenson/Nohria classification for HF patients:
    • Warm and wet (adequate perfusion + congestion) — most common ADHF presentation (~70%)
    • Cold and wet (poor perfusion + congestion) — cardiogenic shock spectrum
    • Warm and dry (adequate perfusion + euvolemic) — compensated HF
    • Cold and dry (poor perfusion + euvolemic) — low-output state without congestion

Management

General Principles

  • Identify and treat the precipitant — ACS, arrhythmia, medication nonadherence, dietary indiscretion, infection, PE, renal failure, uncontrolled HTN
  • Treat respiratory distress first (airway management before diuresis)
  • Obtain daily weights — best metric to follow decongestion progress
  • Goal: net negative fluid balance of 1-2 L/day (weight loss 0.5-1 kg/day); may be more aggressive in acute pulmonary edema[1]
  • Sodium restriction (<2 g/day) and fluid restriction (1.5-2 L/day) if hyponatremic or refractory

Respiratory Support

  • Supplemental O2 — titrate to SpO2 ≥90%
  • Non-invasive positive pressure ventilation (NIPPV) — first-line for acute cardiogenic pulmonary edema
    • Reduces work of breathing, decreases preload and afterload, improves oxygenation
    • CPAP 5-10 cmH2O or BiPAP 10/5 cmH2O, titrate to effect
    • 3CPAP RCT demonstrated reduced mortality and intubation rates vs standard O2[7]
  • Intubation — if NIPPV fails, altered mental status, or inability to protect airway
    • Beware hemodynamic compromise with induction agents and positive pressure ventilation in patients with poor cardiac reserve

Vasodilators

For hypertensive volume-overloaded patients (SBP >110-120 mmHg), especially with acute pulmonary edema

  • IV Nitroglycerin — drug of choice in acute cardiogenic pulmonary edema with adequate BP
    • Start 5-20 mcg/min, titrate q3-5 min up to 200 mcg/min
    • Reduces preload > afterload; improves coronary blood flow
    • High-dose NTG (bolus 200-400 mcg then infusion) can rapidly reduce pulmonary edema symptoms
    • Avoid if SBP <90, severe aortic stenosis, recent PDE5 inhibitor use
  • IV Nitroprusside — arteriolar and venous dilation; useful if severe afterload excess
    • 0.3-0.5 mcg/kg/min; max 2-3 mcg/kg/min
    • Risk of cyanide toxicity, coronary steal; generally second-line
  • Consider nicardipine or clevidipine if concomitant hypertensive emergency

Diuretics

Cornerstone of decongestion therapy

Loop Diuretics (First-Line)

  • IV furosemide is the most commonly used agent
    • Diuretic-naive patients: Start 20-40 mg IV bolus
    • Chronic loop diuretic users: Give IV dose ≥ home oral daily dose (high-dose strategy preferred)
      • The DOSE trial showed high-dose IV furosemide (2.5× oral dose) provided greater symptom relief, diuresis, and weight loss vs. low-dose (1× oral dose), with only transient increases in creatinine[8]
      • No significant difference between bolus q12h vs. continuous infusion on primary outcomes[8]
    • Reassess urine output at 2 hours; if <100-150 mL/hr, double the dose[9]
  • Equivalent doses: furosemide 40 mg IV = bumetanide 1 mg IV = torsemide 20 mg IV
  • Bioavailability: IV furosemide 100%, oral furosemide ~50% (variable; bumetanide and torsemide have more reliable oral absorption)

Diuretic Resistance (Sequential Nephron Blockade)

If inadequate urine output despite escalating loop diuretic dose

  • Add thiazide-type diuretic for synergistic blockade at distal convoluted tubule
    • Metolazone 2.5-5 mg PO (give 30 min before loop diuretic) OR
    • Chlorothiazide 250-500 mg IV (if unable to take PO)
    • Monitor closely for hypokalemia, hyponatremia, hypomagnesemia
  • Add acetazolamide — carbonic anhydrase inhibitor; blocks proximal tubular sodium reabsorption
    • The ADVOR trial (n=519) showed IV acetazolamide 500 mg daily added to loop diuretics significantly increased successful decongestion at 3 days (42.2% vs. 30.5%; RR 1.46, 95% CI 1.17-1.82; p<0.001), with shorter hospital stay and no difference in adverse events[10]
    • Most effective in patients with elevated serum bicarbonate (metabolic alkalosis from chronic diuretic use)
    • Note: ADVOR excluded patients on SGLT2 inhibitors; interaction unknown
  • Consider SGLT2 inhibitor (empagliflozin, dapagliflozin) — osmotic diuresis via glucosuria and natriuresis at proximal tubule; EMPULSE trial supports in-hospital initiation[11]

Monitoring During Diuresis

  • Urine output (Foley if ICU; monitor closely in ED)
  • Daily weight (best metric)
  • BMP q12-24h (K, Mg, Na, Cr) — replete K >4.0, Mg >2.0
  • Reassess volume status clinically (JVP, lung exam, edema, orthopnea)
  • Monitor for signs of over-diuresis: hypotension, worsening renal function, muscle cramps
  • Transient rises in creatinine during diuresis ("pseudo-worsening renal function") are generally acceptable if patient is decongesting and hemodynamically stable[9]

Inotropes

Reserved for "cold and wet" profile (low cardiac output + congestion) — cardiogenic shock spectrum

  • Dobutamine — beta-1 agonist; increases contractility and cardiac output
    • Start 2.5-5 mcg/kg/min, titrate to effect
    • Shorter half-life, more easily titratable than milrinone
  • Milrinone — PDE-3 inhibitor; inotrope + vasodilator ("inodilator")
    • Load 50 mcg/kg over 10 min (often omitted), then 0.375-0.75 mcg/kg/min
    • Renally cleared; accumulates in renal failure
    • Greater vasodilation → more hypotension risk than dobutamine
  • Do NOT start or newly initiate beta-blockers in acute decompensation[9]

Disease-Specific Management

Heart Failure

  • See CHF
  • Initiate or continue GDMT when hemodynamically stable (ARNI/ACEi/ARB, beta-blocker, MRA, SGLT2i)[9]
  • STRONG-HF trial supports rapid up-titration of GDMT post-discharge[12]

Cirrhosis with Ascites

  • Spironolactone is first-line (100 mg/day, max 400 mg/day) ± furosemide in 100:40 ratio
  • Sodium restriction (<2 g/day)
  • Large-volume paracentesis for tense ascites or respiratory compromise
    • Give albumin 6-8 g per liter removed if >5 L removed
  • Avoid NSAIDs (worsen renal sodium retention)
  • Avoid ACEi/ARBs (can precipitate hypotension and hepatorenal syndrome)
  • Maintain MAP >82 mmHg to prevent hepatorenal syndrome

Nephrotic Syndrome

  • Treat underlying cause
  • Sodium restriction (<3 g/day), fluid restriction
  • Loop diuretics (higher doses often needed due to albumin binding in tubular lumen)
  • Add thiazide if refractory
  • Avoid vigorous diuresis → risk of thromboembolism from hemoconcentration, AKI
  • Albumin infusion + furosemide debated; may help in selected patients with severe hypoalbuminemia

Renal Failure

  • Loop diuretics (higher doses needed as GFR declines)
  • Avoid thiazides if GFR <30 (ineffective alone; may work synergistically with loops)
  • Emergent dialysis/ultrafiltration indications:
    • Refractory pulmonary edema
    • Severe hyperkalemia
    • Severe metabolic acidosis
    • Uremic symptoms (pericarditis, encephalopathy, bleeding)

Iatrogenic Volume Overload

  • Reduce or discontinue IV fluids
  • Diuresis as above
  • Reassess fluid strategy (most hospitalized patients do not need maintenance IVF)

Refractory Volume Overload

  • Ensure adequate diuretic dosing before declaring refractory
  • Maximize sequential nephron blockade (loop + thiazide + acetazolamide)
  • Consider hypertonic saline with furosemide (emerging evidence, not yet standard)
  • Ultrafiltration — mechanical fluid removal via venovenous access
    • UNLOAD trial showed benefit in fluid removal; CARRESS-HF showed no benefit over stepped pharmacological therapy and more adverse events[13]
    • Reserve for truly refractory cases
  • Early nephrology and/or advanced HF consultation

Disposition

Admit

  • Acute pulmonary edema requiring IV diuretics, NIPPV, or intubation
  • Hypotension or cardiogenic shock ("cold and wet")
  • New-onset HF (requires workup for etiology)
  • Significant electrolyte derangements
  • ACS or arrhythmia as precipitant
  • Inadequate diuretic response in ED
  • Volume overload with renal failure requiring dialysis consideration
  • Tense ascites requiring paracentesis with hemodynamic instability

ICU Admission

  • Cardiogenic shock or need for vasopressors/inotropes
  • Respiratory failure requiring intubation
  • IV nitroprusside infusion
  • Hemodynamically unstable with ongoing need for titrated infusions

Consider Discharge

  • Mild exacerbation in known HF with preserved hemodynamics
  • Adequate diuretic response in ED (symptom improvement, adequate urine output)
  • Able to resume oral diuretics
  • Reliable follow-up within 24-72 hours (STRONG-HF model supports close post-discharge follow-up)[14]
  • Stable electrolytes, renal function
  • No acute precipitant requiring inpatient management
  • Ensure medication reconciliation, dietary counseling, daily weight monitoring instructions, and clear return precautions

Discharge Checklist

  • Restart/optimize GDMT (for HF patients)
  • Adjusted diuretic regimen with clear instructions
  • Daily weight log with action plan (call if >2 lb gain overnight or >5 lb in a week)
  • Low-sodium diet education
  • Fluid restriction if indicated
  • PCP or cardiology follow-up within 7 days (ideally 24-72 hours post-discharge)

See Also

External Links

References

  1. ↑ 1.0 1.1 1.2 Volume Overload. Merck Manual Professional Edition. Revised May 2024. https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/fluid-metabolism/volume-overload
  2. ↑ Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med. 1988;319(16):1065-1072.
  3. ↑ Arrigo M, Jessup M, Mullens W, et al. Acute heart failure. Nat Rev Dis Primers. 2020;6(1):16.
  4. ↑ Guo A, Gu Y, Wang R, et al. Acute Heart Failure: From The Emergency Department to the Intensive Care Unit. Cardiol Rev. 2024;32(3):217-226.
  5. ↑ Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167.
  6. ↑ Pivetta E, Goffi A, Lupia E, et al. Lung Ultrasound-Implemented Diagnosis of Acute Decompensated Heart Failure in the ED: A SIMEU Multicenter Study. Chest. 2015;148(1):202-210.
  7. ↑ Gray A, Goodacre S, Newby DE, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008;359(2):142-151.
  8. ↑ 8.0 8.1 Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. doi:10.1056/NEJMoa1005419
  9. ↑ 9.0 9.1 9.2 9.3 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063
  10. ↑ Mullens W, Dauw J, Martens P, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. 2022;387(13):1185-1195. doi:10.1056/NEJMoa2203094
  11. ↑ Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574.
  12. ↑ Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF). Lancet. 2022;400(10367):1938-1952.
  13. ↑ Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296-2304.
  14. ↑ Mebazaa A, Davison B, Chioncel O, et al. STRONG-HF. Lancet. 2022;400(10367):1938-1952.
Retrieved from "https://www.wikem.org/w/index.php?title=Volume_overload&oldid=386239"